metricas
covid
Buscar en
Annals of Hepatology
Toda la web
Inicio Annals of Hepatology P- 50 SEROPREVALENCE OF HEPATITIS E VIRUS IN HIV-INFECTED PATIENTS FROM ROSARIO,...
Información de la revista
Vol. 28. Núm. S1.
Abstracts of the 2022 Annual Meeting of the ALEH
(marzo 2023)
Compartir
Compartir
Descargar PDF
Más opciones de artículo
Vol. 28. Núm. S1.
Abstracts of the 2022 Annual Meeting of the ALEH
(marzo 2023)
Acceso a texto completo
P- 50 SEROPREVALENCE OF HEPATITIS E VIRUS IN HIV-INFECTED PATIENTS FROM ROSARIO, SANTA FE
Visitas
233
Julián Acosta1, Alceo Galimberti2, Federico Marziali1, Fernando Bessone2, Alejandro Costaguta3, Damián Águila4, Sergio Lupo4, Bruno Rocha De Lima4, Hugo Tanno2, Virginia Reggiardo2, Daniela Gardiol1, Ana Laura Cavatorta1
1 Institute of Molecular and Cellular Biology of Rosario. Virology Area/CONICET-UNR, Rosario, Argentina
2 Department of Gastroenterology and Hepatology, Centenary Provincial Hospital, Faculty of Medicine -UNR, Rosario, Argentina, Argentina
3 Gastroenterology and Hepatology Service, Children´s Sanatorium / Dr. J.R. Villavicencio Foundation, Rosario, Argentina
4 Medical Clinic Service, Centenary Provincial Hospital, Faculty of Medicine-UNR, Rosario, Argentina
Este artículo ha recibido
Información del artículo
Suplemento especial
Este artículo forma parte de:
Vol. 28. Núm S1

Abstracts of the 2022 Annual Meeting of the ALEH

Más datos
Introduction and Objectives

Although HEV infection is asymptomatic or self-limiting in most individuals, in immunocompromised patients, such as those infected with HIV, viral replication can persist for more than three months leading to chronic infection with progression to cirrhosis. Argentina is considered a country with low endemicity for HEV; however, seroprevalence data in HIV-infected populations are scarce and, to date, there are very few reports that provide accurate information on the impact of HEV infection in these immunosuppressed patients in our region. This study aimed to evaluate the prevalence of HEV infection in HIV-positive individuals from Rosario, Santa Fe.

Materials and Methods

We evaluated 97 HIV-positive individuals (19-74 years old; male=64) from Rosario. A blood serum sample was obtained from each patient after written informed consent. IgG and IgM a-HEV were analyzed by ELISA and HEV RNA by the RT-qPCR method previously optimized in our laboratory. As a control group, 154 blood donors (18-62 years old; male=90) were studied.

Results

The results indicate a seroprevalence of IgG a-HEV of 5.2% (5/97) in HIV individuals compared to 3.2% obtained in the control population (p>0.05). These five positive samples corresponded to male individuals and all were negative for IgM a-HEV. HEV RNA was not detected in any of the 97 samples tested, ruling out acute HEV infection

Conclusions

The results indicate a higher prevalence of IgG a-HEV in the HIV-positive population compared to the control group. The absence of HEV RNA in all the samples analyzed allows discarding active infections that can course with negative serology in this particular group of immunosuppressed individuals. This work provides updated data on the seroprevalence of IgG a-HEV in populations at risk, such as HIV-positive patients from our region.

El Texto completo está disponible en PDF
Descargar PDF
Opciones de artículo
es en pt

¿Es usted profesional sanitario apto para prescribir o dispensar medicamentos?

Are you a health professional able to prescribe or dispense drugs?

Você é um profissional de saúde habilitado a prescrever ou dispensar medicamentos

Quizás le interese:
10.1016/j.aohep.2023.100959
No mostrar más